Publicaciones en colaboración con investigadoras/es de Hospital Universitario 12 de Octubre (41)

2024

  1. Novel risk loci for COVID-19 hospitalization among admixed American populations

    eLife, Vol. 13

  2. Prodromic Inflammatory–Oxidative Stress in Peritoneal Leukocytes of Triple-Transgenic Mice for Alzheimer’s Disease

    International Journal of Molecular Sciences, Vol. 25, Núm. 13

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Dissimilar-at-boron N-BODIPYs: from light-harvesting multichromophoric arrays to CPL-bright chiral-at-boron BODIPYs

    Organic Chemistry Frontiers, Vol. 10, Núm. 23, pp. 5834-5842

2022

  1. Acoustophoretic particle manipulation in hybrid solid/gel resonators

    Frontiers in Physics, Vol. 10

  2. Lactoferrin as Immune-Enhancement Strategy for SARS-CoV-2 Infection in Alzheimer’s Disease Patients

    Frontiers in Immunology, Vol. 13

  3. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

  4. Optimization of levetiracetam dosing regimen in critically ill patients with augmented renal clearance: a Monte Carlo simulation study

    Journal of Intensive Care, Vol. 10, Núm. 1

2021

  1. Accelerated immunosenescence, oxidation and inflammation lead to a higher biological age in COPD patients

    Experimental Gerontology, Vol. 154

  2. Paliperidone Reversion of Maternal Immune Activation-Induced Changes on Brain Serotonin and Kynurenine Pathways

    Frontiers in Pharmacology, Vol. 12

  3. Population pharmacokinetics of levetiracetam and dosing evaluation in critically ill patients with normal or augmented renal function

    Pharmaceutics, Vol. 13, Núm. 10

  4. Standardizing salivary lactoferrin measurements to obtain a robust diagnostic biomarker for alzheimer’s disease

    Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 13, Núm. 1

2020

  1. Decreased salivary lactoferrin levels are specific to Alzheimer's disease

    EBioMedicine, Vol. 57, pp. 102834

  2. Impact of augmented renal clearance on the pharmacokinetics of linezolid: Advantages of continuous infusion from a pharmacokinetic/pharmacodynamic perspective

    International Journal of Infectious Diseases, Vol. 93, pp. 329-338

  3. Novel population pharmacokinetic model for linezolid in critically ill patients and evaluation of the adequacy of the current dosing recommendation

    Pharmaceutics, Vol. 12, Núm. 1

2019

  1. Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment

    Journal of Critical Care, Vol. 50, pp. 69-76

2018

  1. Consensus document on exclusion diets in irritable bowel syndrome (IBS)

    Nutricion Hospitalaria, Vol. 35, Núm. 6, pp. 1450-1466

  2. Intranasal administration of TAT-conjugated lipid nanocarriers loading GDNF for Parkinson’s disease

    Molecular Neurobiology, Vol. 55, Núm. 1, pp. 145-155

2017

  1. Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin

    Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 8, pp. 131-138

  2. Effects of HIV-1 gp41-Derived Virucidal Peptides on Virus-like Lipid Membranes

    Biophysical Journal, Vol. 113, Núm. 6, pp. 1301-1310